Insys Therapeutics (INSY) Tops Q4 EPS by 7c

Insys Therapeutics (NASDAQ: INSY) reported Q4 EPS of $0.36, $0.07 better than the analyst estimate of $0.29. Revenue for the quarter came in at $91.1 million versus the consensus estimate of $91.04 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Airbnb Inc. (ABNB) PT Raised to $175 at Jefferies
• DHT Holdings Q2 TCE earnings estimated at $126,700 per day